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ABSTRACT 49 
Current therapeutic options for cryptococcal meningitis are limited by toxicity, global supply and 50 
emergence of resistance.  There is an urgent need to develop additional antifungal agents that 51 
are fungicidal within the central nervous system and preferably orally bioavailable.  The 52 
benzimidazoles have broad-spectrum anti-parasitic activity, but also have in vitro antifungal 53 
activity that includes Cryptococcus neoformans.  Flubendazole (a benzimidazole) has been 54 
reformulated by Janssen Pharmaceutica as an amorphous solid drug nanodispersion to develop 55 
an orally bioavailable medicine for the treatment of neglected tropical diseases such as 56 
onchocerciasis.  We investigated the in vitro activity, the structure-activity-relationships and both 57 
in vitro and in vivo pharmacodynamics of flubendazole for cryptococcal meningitis.  Flubendazole 58 
has potent in vitro activity against Cryptococcus neoformans with a modal MIC of 0.125 mg/L 59 
using European Committee for Antimicrobial Susceptibility Testing (EUCAST) methodology.  60 
Computer models provided an insight into the residues responsible for the binding of 61 
flubendazole to cryptococcal ß-tubulin.  Rapid fungicidal activity was evident in a hollow fiber 62 
infection model of cryptococcal meningitis.  The solid drug nanodispersion was orally 63 
bioavailable in mice with higher drug exposure in the cerebrum.  The maximal dose of 64 
flubendazole (12 mg/kg/day) orally resulted in a ~2 log10CFU/g reduction in fungal burden 65 
compared with vehicle-treated controls.  Flubendazole was orally bioavailable in rabbits, but 66 
there were no quantifiable drug concentrations in the CSF or cerebrum and no antifungal activity 67 
was demonstrated in either CSF or cerebrum.  These studies provide evidence for the further 68 
study and development of the benzimidazole scaffold for the treatment of cryptococcal 69 
meningitis. 70 
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 71 
INTRODUCTION 72 
Cryptococcal meningoencephalitis (herein meningitis) is a common and lethal disease in 73 
immunosuppressed patients (1, 2).  This disease is predominately associated with advanced HIV 74 
infection and has the highest incidence in low to middle income countries (1).  The number of 75 
effective agents is despairingly small (3).  All available induction and maintenance regimens are 76 
constructed with three antifungal agents: amphotericin B (AmB), flucytosine (5FC) and 77 
fluconazole (4).  Each of these compounds has significant adverse effects that include infusional 78 
toxicity (AmB), nephrotoxicity (AmB (5)), bone marrow suppression (AmB and 5FC (5, 6)) and 79 
hepatotoxicity (fluconazole and 5FC (7)).  Moreover, there are significant inherent limitations 80 
that include fungistatic effects (fluconazole; (8)) and the potential emergence of drug resistance 81 
(fluconazole and 5FC; (9–11)).  Thus, there is an urgent imperative to develop new agents.  Orally 82 
bioavailable agents are particularly important given the predominance of this disease in resource 83 
constrained settings. 84 
During the process of screening a compound library against fungal pathogens, it was 85 
noted by us (M.T. & I.C.) that flubendazole has potent in vitro activity against Cryptococcus 86 
neoformans.  A literature search revealed other members of the benzimidazole class (e.g. 87 
albendazole and mebendazole) of anti-parasitic agents had previously been demonstrated to 88 
have potent in vitro activity against Cryptococcus neoformans with minimum inhibitory 89 
concentrations (MICs) of 0.16-0.45 mg/L (12, 13).  The pharmacological target of the 90 
benzimidazoles against Cryptococcus neoformans is ß-tubulin (14).  The antifungal activity of 91 
parenterally administered flubendazole in a murine model of cryptococcal meningitis was 92 
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confirmed by us in a series of preliminary experiments.  Concurrently, we became aware of the 93 
efforts by Janssen Pharmaceutica to develop a new orally bioavailable formulation of 94 
flubendazole that may be active against filariasis and onchocerciasis.  The potential value of this 95 
new formulation as an oral medicine for the treatment of cryptococcal meningitis in resource 96 
poor healthcare settings was therefore evident.   97 
Herein, we describe the in vitro activity, putative structure-activity relationships, and the 98 
in vivo pharmacokinetic-pharmacodynamic relationships of flubendazole against Cryptococcus 99 
neoformans.  A hollow fiber infection model of cryptococcal meningitis was developed as a first 100 
step for exploring dose-exposure-response relationships.  Subsequently, two extensively used 101 
and well-characterized laboratory animal models of cryptococcal meningitis were used to 102 
provide the experimental foundation for the potential use of oral formulations of flubendazole 103 
or its congeners for the treatment of a neglected infection of global significance. 104 
  105 
 o
n
 January 15, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
 
 
7 
RESULTS 106 
In vitro studies 107 
Flubendazole displayed potent in vitro activity (MIC 0.06-0.25 mg/L; Table 1) against C. 108 
neoformans.  The MICs were comparable when EUCAST and CLSI methodology was used. 109 
The flubendazole IC50 against porcine tubulin was 2.38 µM.  Other known tubulin 110 
inhibitors display similar efficacy in this assay (e.g. colchicine IC50 = 1.15 µM (unpublished data), 111 
paclitaxel IC50 = 3.9 µM (15) and vinblastine IC50 = 5.3 µM (15).  These data are consistent with 112 
the known mechanism of action of flubendazole.  113 
In vitro DMPK assessment of commercially available flubendazole powder confirmed a 114 
favorable logD7.4 of 2.9.  Plasma protein binding was 90.6% and there was low metabolic 115 
turnover (Hu Mic Clint = 44 µl/min/mg and Rat Hep Clint = 39 µl/min/106 cells).  However, 116 
aqueous solubility was poor (0.8 µM), which is characteristic of the benzimidazoles.  This in vitro 117 
DMPK assessment was consistent with subsequent in vivo observations (see below).  Poor 118 
aqueous solubility limits absorption through the gut, but once in the bloodstream the drug has 119 
favorable pharmacokinetic properties (e.g. ability to pass through cell membranes, low 120 
metabolism, and high concentrations of free drug) that enable it to reach the effect site.  121 
 122 
Docking Studies 123 
There were two principal non-covalent binding interactions between flubendazole and 124 
the homology model of C. neoformans ß-tubulin.  First, the hydroxyl group of Serine 350 acts as a 125 
hydrogen bond donor and binds the ketone oxygen of flubendazole (Figure 1A).  Second, 126 
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asparagine (Asn) 247 acted as a hydrogen bond donor via the primary amide with the ketone of 127 
the carbamate on flubendazole, but also acted as a hydrogen bond acceptor through the primary 128 
carbonyl group of Asn247 and the N-H on the benzimidazole core.  There were also several 129 
hydrophobic interactions deeper in the binding pocket that involved the benzene ring and the 130 
fluorine of flubendazole. 131 
Docking studies of flubendazole and human ß-tubulin (Fig 1B) showed that both the N-H 132 
of the benzimidazole core and the N-H of the carbamate are hydrogen bond donors (Figure 1B) 133 
to the primary amide of the side chain of Asn247.  As for the C. neoformans interaction, there 134 
were hydrophobic interactions present from the para-substituted benzene and the hydrophobic 135 
binding pocket.  There was a lack of a hydrogen bond acceptor role from the ketone oxygen. This 136 
is due to the replacement of Ser350 from the C. neoformans active site with Lys350 in humans.  137 
 138 
Hollow Fiber Infection Model of Cryptococcal Meningoencephalitis 139 
Rapid fungicidal activity was observed in the hollow fiber infection models.  Controls 140 
grew from an initial density of approximately log10CFU/mL 6 to log10CFU/mL 8-9.  Following the 141 
administration of flubendazole there was a progressive decline in the fungal density in the 142 
hollow fibre in all arms.  There was an exposure-dependent decline in fungal burden.  143 
 144 
Preliminary Studies to Demonstrate In vivo Efficacy of Flubendazole 145 
There was no demonstrable antifungal effect of orally administered flubendazole as pure 146 
compound when formulated with sterile distilled water, 0.05% polysorbate 80 in PBS, 5% DMSO, 147 
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10% PEG400 or 85% hydroxyl-propyl-ß-cyclodextrin (data not shown).  Antifungal activity could 148 
only be established when pure flubendazole formulated with polysorbate 80 (Tween 80) and 149 
injected s.c. to form a depot.  Presumably, formulation with polysorbate 80 solubilized 150 
flubendazole to an extent that enabled it to become systemically bioavailable.  However, this 151 
was only observed when flubendazole was administered s.c.  This parenteral regimen resulted in 152 
a modest reduction in fungal burden of 1-2 log10CFU/g compared with vehicle-treated controls 153 
(data not shown).  A limited PK study with concentrations measured at a single time-point the 154 
end of the experiment also confirmed flubendazole concentrations were quantifiable in plasma 155 
and the cerebrum of mice (data not shown).   156 
These preliminary pharmacokinetic and pharmacodynamic data provided the impetus for 157 
further detailed experiments examining the pharmacodynamics of a new orally bioavailable solid 158 
drug nano-dispersion against Cryptococcus neoformans developed by Janssen. 159 
 160 
Pharmacokinetic and Pharmacodynamic Studies of the Flubendazole Nanoformulation in Mice  161 
When flubendazole was formulated as a solid drug nano-dispersion, it was rapidly 162 
absorbed after oral dosing and plasma concentrations were readily quantifiable at the first 163 
sampling point (i.e. 0.5 hrs. post dose; Figure 3).  The pharmacokinetics were linear, with bi-164 
exponential clearance from the bloodstream with a mean and median value of 0.039 and 0.026 165 
L/h, respectively (Figure 3).  The pharmacokinetic parameters are summarized in Table 2.  There 166 
was rapid and extensive distribution of drug to the cerebrum of mice and concentrations of 167 
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flubendazole were consistently higher than those observed in plasma.  The AUCserum: 168 
AUCcerebrum was 1:4.44. 169 
Flubendazole had a significant and discernible antifungal effect in mice.  Use of the 170 
highest dosage in this study (12 mg/kg) resulted in approximately a 2-3 log reduction in fungal 171 
burden relative to controls (Figure 4).  This regimen was limited by maximum permissible 172 
volumes for oral administration for mice (i.e. 20 mL/kg).  In a single experiment in which the 173 
effect of 6 mg/kg q12h (i.e. 12 mg/kg/day) was compared to 12 mg/kg/day there was no 174 
difference in antifungal effect (data not shown).  This is preliminary evidence that the AUC is 175 
likely to be the dynamically linked index for flubendazole against Cryptococcus neoformans. 176 
 177 
Pharmacokinetic and Pharmacodynamic Studies in Rabbits 178 
The PK in rabbits was linear with a similar concentration-time profile to that observed in 179 
mice.  The plasma concentration-time profiles in rabbits had a similar shape to those of mice, but 180 
were lower for the dosages used in this study.  Despite readily quantifiable plasma 181 
concentrations, there was no quantifiable drug concentrations in either the CSF or the cerebrum 182 
of rabbits at the time of sacrifice. 183 
There was no demonstrable antifungal effect in rabbits receiving 6 mg/kg/day.  There 184 
may be some effect in rabbits receiving 22.5 mg/kg q24h, but if present the effect was small and 185 
these assessments were limited by few animals.  There were no statistically significant 186 
differences in the area under the log10CFU/g-time curve for each regimen even though this may 187 
be a relatively insensitive test of antifungal effect.  Furthermore, there was no difference in the 188 
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11 
fungal burden in the cerebrum at the end of the experiment for any of the groups of rabbits 189 
used in this study. 190 
  191 
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 192 
DISCUSSION 193 
When given subcutaneously, flubendazole has striking activity in laboratory animal 194 
models of filarial diseases such as onchocerciasis and lymphatic filariasis (16).  Janssen developed 195 
a novel amorphous solid drug nanodispersion to provide a potential new therapeutic option for 196 
patients with these neglected tropical diseases.  The systemic drug exposure that was enabled by 197 
the new formulation mandated GLP toxicology studies before progression to early phase clinical 198 
studies.  It was already known that flubendazole is clastogenic (i.e. induces chromosomal 199 
breakages) and aneugenic (i.e. induces aneuploidy), as well as embryotoxic (17).  GLP toxicology 200 
studies were performed by Janssen in the rat (5, 15 and 30 mg/kg/day in male rats and 2.5, 5 and 201 
10 mg/kg/day in female rats) and in the dog (20, 40 and 100 mg/kg/day) for 2 weeks.  These 202 
experiments showed evidence of toxicity related to the pharmacological activity of flubendazole 203 
in the gastrointestinal tract, lymphoid system and the bone marrow, as well as testicular toxicity 204 
in both rat and dog.  In the dog, liver toxicity was also observed.  As a result, the development 205 
program was stopped based on an unacceptable risk/benefit profile in humans.  This also halted 206 
our own efforts to develop flubendazole for cryptococcal meningitis. 207 
Flubendazole has striking in vitro activity against Cryptococcus neoformans that was 208 
evident in the MIC testing and the pharmacodynamic studies in the hollow fiber infection model.  209 
There was modest antifungal activity in the murine model, which is not as prominent as that 210 
previously described by us for fluconazole, amphotericin B deoxycholate or liposomal 211 
amphotericin B (8, 18, 19).  There was no unequivocal antifungal activity in the rabbit model of 212 
cryptococcal meningoencephalitis, which is largely explained by the absence of detectable 213 
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flubendazole concentrations in the cerebrum or CSF (despite readily quantifiable plasma 214 
concentrations).  The in vitro susceptibility testing and data from the hollow fiber model suggests 215 
that flubendazole is highly potent and fungicidal if able to reach its fungal target in sufficient 216 
concentrations.  The diminished activity in the mouse (relative to historical controls) and absence 217 
of effect in the rabbit (with non-quantifiable concentrations in the cerebrum and CSF) further 218 
support this conclusion.  Hence, successful exploitation of the benzimidazole backbone requires 219 
careful attention to physiochemical properties that promote absorption across the gut and the 220 
ability to partition into sub-compartments of the CNS.   221 
Flubendazole did not display a comparable degree of in vivo activity to other first-line 222 
agents for cryptococcal meningitis (i.e. fluconazole and amphotericin B formulations).  Even if 223 
the safety profile was not problematic, there is insufficient prima facie evidence from either the 224 
murine or rabbit models to further study flubendazole as monotherapy for induction therapy in 225 
phase II clinical studies.  Nevertheless, additional approaches such as the combination with other 226 
antifungal agents for induction therapy and/or used as longer-term consolidation and 227 
maintenance therapy may have been possible. 228 
The potential of derivatives of flubendazole to be useful human medicines depends on 229 
the differential activity between cryptococcal and human proteins.  Characterization of the β-230 
tubulin genes of C. neoformans has been undertaken and two C. neoformans β-tubulin genes 231 
(TUB1 and TUB2) have been identified.  TUB1 was identified as the primary target of the 232 
benzimidazole class of compounds through gene characterization and expression (14).  There is 233 
90% homology between fungal TUB1 and human β-tubulin, although the former has not been 234 
crystallized and this has prevented definitive structure-activity-relationship docking studies.  The 235 
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ability to develop new agents based on a benzimidazole scaffold or to further exploit β-tubulin as 236 
a pharmacological target will depend on the degree of differential activity of a benzimidazole 237 
with these proteins.  The differential binding identified through the docking and homology 238 
modelling of both human β-tubulin (20) and C. neoformans var. grubii serotype A (strain H99) β-239 
tubulin (14) to the Bos Taurus 1SA0 β-tubulin crystal structure implies an increased number of 240 
binding interactions with C. neoformans β-tubulin.  This may provide the potential to exploit this 241 
differential binding to establish a favorable therapeutic index.  It is also worth emphasizing that 242 
the benzimidazoles may have additional targets beyond β-tubulin that have the further potential 243 
to provide differential activity between human and fungal proteins, but this requires further 244 
investigation (21–24).   245 
The potential utility of congeners of flubendazole now rests with medicinal chemistry 246 
programs.  Compounds must be synthesized that exhibit differential activity against cryptococcal 247 
and human tubulin (if that is possible) so that there is an acceptable safety margin and toxicity 248 
profile.  Furthermore, the compound must be able to traverse the gut (compounds that are not 249 
orally bioavailable will be less clinically valuable) and then the blood-brain-barrier to achieve 250 
concentrations that are ideally fungicidal.  The latter will be promoted by new molecules that 251 
low molecular weight lipophilic compounds that are not substrates for active pumps such as P-252 
glycoprotein.  This will undoubtedly also require the use of novel formulation technologies to 253 
ensure compounds that are poorly soluble to become useful agents for disseminated infections.   254 
  255 
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METHODS 256 
Drug 257 
Flubendazole that was used for determination of MICs, hollow fibre experiments and 258 
preliminary murine experiments was purchased from Sigma.  Subsequently, definitive 259 
pharmacokinetic-pharmacodynamic experiments that were performed with orally administered 260 
flubendazole used a solid drug nano-dispersion formulation of flubendazole developed by 261 
Janssen Pharmaceuticals (batch BREC-1113-070, Janssen Pharmaceuticals).  The stability of this 262 
formulation in liquid and solid phases was confirmed for 1 and 6 months, respectively.  263 
A 10 mg/mL methylcellulose 4000cps stock solution (100 mL batch) was prepared from a 264 
dispersion of 1 g methylcellulose 4000cps with stirring into 70 mL demineralized water heated to 265 
70°C-80°C. The solution was stirred for at least 15 minutes followed by the addition of 20 mL of 266 
demineralized water.  The mixture was stirred until it reached room temperature and was then 267 
made up to 100 mL with demineralized water.  A total of 50mL of 6 mg/mL spray dried powder 268 
suspension was then prepared (this corresponds with 0.6 mg/mL of flubendazole as the active 269 
dose in 0.5% methylcellulose).  A total of 24.70 g of demineralized water was added to a 50-mL 270 
clear glass vial.  A total of 0.30 g of spray dried drug was added to the vial which was then closed 271 
with a stopper.  The vial was vortexed and then homogenized using a polytron disperser.  A 25-272 
mL stock solution of methylcellulose 4000cps was added and the vial was vortexed.  The 273 
suspension was refrigerated at 5°C until dosing for a maximum of 14 days.  Prior to dosing the 274 
suspension was vortexed. 275 
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16 
Strains 276 
The initial in vitro susceptibility testing was performed with H99 (ATCC 208821).  An 277 
additional 49 clinical isolates were obtained from the National Centre for Microbiology Instituto 278 
de Salud Carlos III, Madrid, Spain (courtesy Ana Alastruey-Izquierdo and Manual Cuenca-Estrella).  279 
These isolates were identified to species level using standard microbiological techniques. 280 
Minimum Inhibitory Concentrations 281 
The minimum inhibitory concentration of flubendazole against H99 (ATCC 208821) and 282 
the 49 isolates was estimated using methodology of the European Committee on Antimicrobial 283 
Susceptibility Testing (EUCAST; (25)) and Clinical Sciences Laboratory Institute (CLSI; (26)).  The 284 
endpoint for MIC determination using EUCAST and CLSI was 50% for both methods.  MICs were 285 
performed in triplicate. 286 
Porcine Tubulin Polymerization Assay 287 
Porcine tubulin is generally used as a surrogate for human tubulin because of its high 288 
degree of homology (95%) (27).  In the studies described herein, this assay was used to 289 
determine the extent of interaction between flubendazole and its putative target as also occurs 290 
for assessment of the binding of antineoplastic agents (28, 29).  The commercially available 291 
porcine tubulin assay (BK011P, Cytoskeleton, Inc. Denver, USA) quantifies the time-dependent 292 
polymerization of tubulin to microtubules and thus the ability of tubulin inhibitors to disrupt this 293 
process.  294 
The porcine tubulin assay was performed according to the manufacturer’s instructions. 295 
Briefly, the 96-well assay plate was pre-warmed to 37°C prior to use.  Five μL of test 296 
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compound(s) and controls at 0, 1.25, 2.5, 5, 10 μM were aliquoted into each well and pre-297 
warmed for 1 min.  Colchicine and DMSO were used as positive and negative controls, 298 
respectively.  Polymerization was initiated by mixing 45 μL of reaction buffer that contained 2 299 
mg/mL of purified porcine brain tubulin, 10 μM fluorescent reporter, PEM buffer (80 mM PIPES, 300 
0.5 mM EGTA, 2 mM MgCl2, pH 6.9), 1mM GTP and 20.3% glycerol.  Tubulin polymerization was 301 
followed by an increase in fluorescence intensity due to the incorporation of a fluorescence 302 
reporter into microtubules as polymerization occurred.  The change in fluorescence was 303 
measured using an excitation and emission wavelength of 360 nm and 450 nm, respectively 304 
every 1-min for 1-hr. at 37°C using a Varioskan multimode plate reader (Thermo scientific Inc.).  305 
All data points were acquired in triplicate and IC50 values were calculated with GraphPad Prism.  306 
The IC50 value was defined as the drug concentration required to inhibit tubulin polymerization 307 
by 50% compared with negative control. 308 
 309 
Homology Modeling and Docking Studies 310 
While the amino acid sequence of cryptococcal ß-tubulin is known (74% homology with 311 
human β-tubulin), the protein has not been crystallized.  A homology model was therefore 312 
developed to investigate differential binding modes of flubendazole within C. neoformans and 313 
human β-tubulin.  Molecular modelling (Modeller version 9.14, https://salilab.org/modeller/) of 314 
both human β-tubulin (20) and C. neoformans var. grubii serotype A (strain H99) β-tubulin (14) 315 
was undertaken using the Bos Taurus 1SA0 β-tubulin crystal structure (identity: 364/447 (81.4%); 316 
similarity: 405/447 (90.6%)).  317 
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18 
Virtual flubendazole was built in the molecular modelling software Spartan 318 
(Wavefunction Inc., Irvine, USA) and energy minimized.  Flubendazole was then subjected to a 319 
piecewise linear potential (ChemPLP) docking protocol (a scoring function to provide confidence 320 
in the docking pose adopted by the molecule), consisting of 10 genetic algorithm (GA) runs 321 
before visualization using the molecular visualization system PyMOL with the top scoring 322 
compound depicted in Figure 1. The active site binding interactions were selected by identifying 323 
those amino acid residues within 4Å of flubendazole when docked into the β- tubulin binding 324 
site.  Polar contacts between flubendazole and the surrounding amino acids were identified, 325 
which aided in the identification of hydrogen bonding interactions that are key in determining 326 
the efficacy of a drug against its pharmacological target.  327 
Finally, hydrogen bond donor interactions, as well as hydrophobic interactions were 328 
identified using the pharmacophore (i.e. an abstract description of molecular features that in this 329 
case are necessary for molecular recognition of flubendazole by β-tubulin) search software Zinc 330 
Pharmer (https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gks378) at 4Å for 331 
hydrogen bonding interactions and 6Å for hydrophobic interactions.  332 
 333 
Hollow Fiber Model of Cryptococcal Meningoencephalitis 334 
A new hollow fiber infection model (HFIM) was developed to investigate the in vitro 335 
pharmacodynamics of flubendazole against C. neoformans.  The same cartridges (FiberCell 336 
Systems, Frederick, MD, USA) and configuration as previously described for bacterial pathogens 337 
was used (see for example (30)).  The extra-capillary space of each cartridge was inoculated with 338 
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40 mL of a suspension containing log10CFU/mL 6 of C. neoformans var. grubii (ATCC 208821; 339 
H99).  Yeast-extract-peptone-dextrose (YPD) medium was pumped from the central 340 
compartment through the cartridge and back again using a peristaltic pump (205 U; Watson-341 
Marlow, United Kingdom).  The HFIM was incubated at 37°C in ambient air.  The time-course of 342 
fungal growth was determined by removing 1 mL from the extra-capillary space of the cartridge 343 
and plating serial 10-fold dilutions to YPD agar. 344 
The relationship between flubendazole drug exposure and it effect was explored using a 345 
range of drug exposures.  Since there is no information on the pharmacokinetics of flubendazole 346 
in humans, we attempted to produce AUCs that were comparable to those observed in mice.  347 
Various dosages of flubendazole were administered q24h by infusion over 1 hour for 8 days to 348 
the central compartment using a programmable syringe driver (Aladdin pump; World Precision 349 
Instruments, United Kingdom).  There was a 24-hour delay in the initiation of flubendazole 350 
therapy post inoculation.  To generate first-order pharmacokinetics, fresh YPD medium was 351 
pumped into the central compartment, and the same volume of drug-containing medium was 352 
simultaneously removed and discarded.  Positive controls of currently licensed agents were not 353 
studied in these experiments. 354 
 355 
Murine model of cryptococcal meningoencephalitis  356 
A previously described (31) and well-characterized murine model of cryptococcal 357 
meningitis was used to investigate the pharmacodynamics of flubendazole.  All laboratory animal 358 
experiments were performed under UK Home Office project license PPL40/3630 and were 359 
 o
n
 January 15, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
 
 
20 
approved by the University of Liverpool’s Animal Welfare Ethics Review Board.  Male CD1 mice 360 
were purchased from Charles River and were 20-30 grams at the time of experimentation.  An 361 
inoculum of 3 x 108 CFU in 0.25 mL was used for each mouse.  Groups of mice (n=3) were serially 362 
sacrificed throughout the experimental period.  The brains were removed and homogenized.  363 
Serial 10-fold dilutions were plated to YPD agar supplemented with chloramphenicol to 364 
enumerate the total fungal burden.  Plates were incubated in air at 30○C for at least 48 hours. 365 
 366 
Pharmacokinetic and Pharmacodynamic Studies of Flubendazole in Mice   367 
Preliminary evidence for the efficacy of flubendazole was obtained by dissolving pure 368 
compound in a variety of excipients that included cyclodextrin (F2G, Eccles, UK), DMSO [5%] and 369 
polysorbate 80 [10%] and injecting it subcutaneously q24h.  Ultimately, only s.c. injection with 370 
Tween80 showed any effect.  This experiment provided the impetus to further examine the 371 
orally bioavailable formulation developed by Janssen (see above).  372 
The pharmacokinetics of oral flubendazole was determined with two independently 373 
conducted experiments.  Treatment was initiated 24 hrs. post-inoculation.  Dosages of 2-12 374 
mg/kg were used.  Only the first dosing interval was studied.  A serial sacrifice design was used 375 
with groups of n=3 mice that were sacrificed at 0.5, 1, 2, 8 and 24 hrs. post-inoculation.   376 
The pharmacodynamics of oral flubendazole was estimated over the course of three 377 
separate independently conducted experiments.  Groups of n=3 mice were sacrificed at time = 2, 378 
24, 48, 96, 144 and 168 hours post inoculation.  Dose finding studies were performed using 379 
flubendazole 2, 4, 6, 8, and 12 mg/kg q24h orally.  The upper dosage was limited by the volume 380 
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restrictions for mice imposed Home Office project license PPL40/3630.  A fourth experiment 381 
compared 12 mg/kg q24 with 6 mg/kg q12h to examine whether more fractionated regimens 382 
provided any additional antifungal effect.  383 
Rabbit model of cryptococcal meningitis  384 
A previously described and well-characterized rabbit model of cryptococcal 385 
meningoencephalitis (32) was used to further investigate the pharmacodynamics of 386 
flubendazole.  Male New Zealand White rabbits were purchased from Harlan.  Rabbits weighed 387 
2.5-3 kg at the time of experimentation.  Rabbits were immunosuppressed intramuscularly with 388 
hydrocortisone 10mg/kg day -1 relative to infection and then daily throughout the experiment. 389 
Cryptococcal meningoencephalitis was induced with the intra-cisternal inoculation of 390 
0.25 mL of a suspension containing 3.8 x 108 CFU/mL under general anesthesia (induced with 391 
metedomidine and ketamine).  This inoculum results in progressive infection that manifests as an 392 
increase in fungal burden in the CSF and reproducible encephalitis.  There is minimal clinical 393 
disease with no demonstrable neurological signs in the experimental period.  Mortality always 394 
occurred in the context of cisternal tapping and repeated anesthesia rather than from 395 
progressive infection.  396 
Pharmacodynamic and Pharmacokinetic studies in Rabbits 397 
PK-PD relationships in the rabbit were estimated in two independently conducted 398 
experiments consisting of 6 rabbits in each experiment.  Rabbits were placed under general 399 
anesthesia for removal of CSF via intra-cisternal tapping at 48 hour intervals.  Over the course of 400 
the two experiments there were n=3 controls (1 rabbit died after being tapped), flubendazole 6 401 
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mg/kg q24h (n=6) and 22.5 mg/kg q24h (n=6).  The maximum dosage that was used was limited 402 
by the formulation provided by Janssen and the limits of oral gavage in rabbit (15 mL/kg/day).  403 
Treatment was initiated 48 hrs. post-inoculation, and continued for 10 days, after which time all 404 
rabbits were sacrificed.  Thus, the total duration of the experiment was 288 hours. 405 
 406 
Measurement of flubendazole concentrations using LC/MS/MS 407 
Flubendazole concentrations in all matrices were measured using a validated ultrahigh-408 
performance liquid chromatography tandem mass spectrometry implemented on an Agilent 409 
6420 Triple Quad Mass spectrometer and an Agilent 1290 infinity LC system (Agilent 410 
Technologies UK Ltd, Cheshire, UK).  Flubendazole was extracted by protein precipitation by 411 
adding 300 µL of a 50:50 mix of acetonitrile:methanol that contained the internal standard (6,7-412 
Dimethyl-2,3-di(2-pyridyl) quinoxaline; Sigma Aldrich, Dorset, UK) at a final concentration of 1 413 
mg/L to 30µL of each matrix.   414 
The extraction was performed in 96-well Sirocco protein precipitation plates (Waters, 415 
UK).  Samples were then shaken for 2 mins and then extracted using a 96-postive pressure 416 
manifold (Waters, UK).  A total of 200 µL of the supernatant was removed and placed in a 96 well 417 
plate.  One µL was injected on an Agilent a Zorbax Eclipse Plus C18 column (2.1 by 50 mm, 1.8-m 418 
particle size; Agilent Technologies UK Ltd, Cheshire, UK).  Chromatographic separation was 419 
achieved using a gradient with the starting conditions of a 60:40 mix of A (0.1% formic acid in 420 
water) and B (0.1% formic acid in acetonitrile).  The ratio of A:B changed to 20:80 over 2 minutes 421 
and then returned to the starting conditions (60:40) for 1 minute of equilibration.  422 
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 The mass spectrometer was operated in multiple reaction monitoring (MRM) scan mode 423 
in positive polarity. The precursor ion for flubendazole and internal standard was 314.1m/z, and 424 
313.15 m/z, respectively. The product ion for flubendazole and internal standard was 282.1 m/z 425 
and 284.1 m/z, respectively.  The source parameters were set as 4000 V for capillary voltage, 426 
350°C for gas temperature, and 60 lb/in2 for the nebulizer gas.   427 
The standard curve for flubendazole encompassed the concentration range of 0.0005-8.0 428 
mg/L and was constructed using the respective blank matrix.  The limit of quantitation was 429 
0.0005 mg/L and the CV% was 12.7% over the concentration range 0.0005-8 mg/L. and the intra 430 
and inter-day variation was <12% for all matrices. 431 
Mathematical modeling 432 
The pharmacokinetic and pharmacodynamic datasets from mice were modelled using the 433 
program Pmetrics (33) and the following five inhomogeneous differential equations: 434 
Eq. 1 𝑋𝑃(1) =  𝐵(1) − 𝐾𝑎 ∗ 𝑋(1) 435 
Eq. 2  𝑋𝑃(2) =  𝐾𝑎 ∗ 𝑋(1) − (
𝑆𝐶𝐿
𝑉
) ∗ 𝑋(2) − 𝐾𝑐𝑝 ∙ 𝑋(2) + 𝐾𝑝𝑐 ∙ 𝑋(3)  − 𝐾𝑐𝑏 ∙ 𝑋(2) + 𝐾𝑏𝑐 ∙436 
𝑋(4)  437 
Eq. 3 𝑋𝑃(3) =  𝐾𝑐𝑝 ∙ 𝑋(2) − 𝐾𝑝𝑐 ∙ 𝑋(3) 438 
Eq. 4 𝑋𝑃(4) =  𝐾𝑐𝑝 ∙ 𝑋(2) − 𝐾𝑝𝑐 ∙ 𝑋(4) 439 
Eq. 5 𝑋𝑃(5) =  𝐾𝑔𝑚𝑎𝑥 ∙ (1 − (
(
𝑋(4)
𝑉
)
𝐻𝑔
𝐶50𝑔𝐻𝑔+(
𝑋(4)
𝑉
)
𝐻𝑔))
 
∗ (1 − (
𝑋(5)
𝑝𝑜𝑝𝑚𝑎𝑥
)) ∗ 𝑋(5)  440 
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The system parameters and their units are as follows: B(1) (mg) represents the bolus 441 
input of flubendazole into the gut.  Ka (h-1) is the first order rate constant collecting the gut and 442 
the central compartment; SCL (L/h) is the clearance of flubendazole from the central 443 
compartment; V (L) is the volume of the central compartment; Kcp (h-1) and Kpc (h-1) are the 444 
first-order inter-compartmental rate constants.  Kgmax (log10CFU/g/h) and kkillmax 445 
(log10CFU/g/h) are the maximal rates of cryptococcal growth and flubendazole-induced kill, 446 
respectively.  POPMAX (CFU/g) is the maximum theoretical fungal density.  C50g (mg/L) and C50k 447 
(mg/L) are the concentrations of flubendazole that induce half-maximal effects on growth and 448 
kill, respectively.  Hg and Hk are the respective slope functions for growth and kill.  The initial 449 
condition (CFU/g; not shown in the equations) is the fungal density immediately following 450 
inoculation, and is estimated along with other parameters.  451 
Equations 1, 2, 3 and 4 are pharmacokinetic equations that describe the movement of 452 
drug from the gut, throughout the body and into the brain.  Equation 1 describes the movement 453 
of drug from the gut.  Equation 2 describes the rate if change of flubendazole in the central 454 
compartment (plasma) with first-order clearance and movement of drug to and from both a 455 
peripheral (unmeasured) compartment and the cerebrum.  Equations 3 and 4 describe the rate 456 
of change of drug in the peripheral and cerebral compartments, respectively.  The 457 
pharmacodynamics of flubendazole against Cryptococcus neoformans is described by Equation 5, 458 
which has terms that describe the capacity limited growth of Cryptococcus, flubendazole-459 
induced suppression of growth and drug-induced fungal killing.  The antifungal activity in the 460 
cerebrum is primarily related to concentrations in the cerebrum.   461 
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A similar model was used to model the PK-PD data from rabbits, but there were some 462 
differences.  Firstly, no drug was detectable in the brain or the CSF.  Therefore, we let plasma 463 
concentrations of drug drive the antifungal effect and did not attempt to model the 464 
concentration of drug in the central nervous system (as was the case for mice).  We directly 465 
linked plasma concentrations with the antifungal effect.   466 
  467 
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 573 
Table 1. MIC distributions of flubendazole against C. neoformans isolates using CLSI and EUCAST 574 
methodologies. 575 
              
Methodology 
Number 
of strains 
Number of isolates with MIC (mg/L) of: 
0.03 0.06 0.125 0.25 0.5 
EUCASTa 50 1 19 25 5 0 
CLSIb 50 2 40 8 0 0 
        576 
a European Committee for Antimicrobial Susceptibility Testing 577 
b Clinical Laboratory Sciences Institute 578 
 579 
  580 
 o
n
 January 15, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
 
 
33 
 581 
Table 2. Parameter Values from the PK-PD model fitted to mice 582 
 583 
Parameter (Units) Mean Median Standard Deviation 
Ka (h-1) 11.312 14.895 6.594 
SCL/F (L/h) 0.039 0.026 0.031 
Vc/F (L) 0.051 0.069 0.033 
Kcp (h-1) 15.741 15.404 6.806 
Kpc (h-1) 16.997 16.915 5.962 
Kcb (h-1) 3.446 0.594 4.709 
Kbc (h-1) 0.056 0.056 0.030 
Kgmax (log10CFU/g/h) 0.107 0.098 0.025 
Hg 10.338 5.096 9.782 
C50g (L/h) 2.036 1.681 1.517 
POPMAX (CFU/g) 982934669.178 427055621.187 2281967059.602 
IC (CFU/g) 102.255 116.462 60.966 
Vb/F (L) 0.277 0.146 0.335 
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Ka (h-1) is the first order rate constant collecting the gut and the central compartment; SCL/F 584 
(L/h) is the apparent clearance of flubendazole from the central compartment; V/F and Vb/F (L) 585 
are the apparent volumes of the central compartment and brain, respectively; Kcp (h-1) and Kpc 586 
(h-1) are the first-order inter-compartmental rate constants.  Kgmax (log10CFU/g/h) and kkillmax 587 
(log10CFU/g/h) are the maximal rates of cryptococcal growth and flubendazole-induced kill, 588 
respectively.  POPMAX (CFU/g) is the maximum theoretical fungal density.  C50g (mg/L) and C50k 589 
(mg/L) are the concentrations of flubendazole that induce half-maximal effects on growth and 590 
kill, respectively.  Hg and Hk are the respective slope functions for growth and kill. 591 
  592 
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 593 
 594 
 595 
Figure 1. Homology model of flubendazole docked with both C. neoformans and human β- 596 
tubulin.  The colours are as follows: red sphere: hydrogen bond donors; blue sphere: hydrogen 597 
bond acceptors; yellow sphere: hydrophobic interactions.  The docking pose is visualized with 598 
PyMOL.  Protein is shown as a surface representation coloured 40% transparent light blue.  599 
Flubendazole is represented as sticks composed of carbon (light blue); hydrogen (white); 600 
nitrogen (dark blue); oxygen (red); and fluorine (cyan).  Binding site residues selected around 4 Å 601 
are represented as sticks with carbon (green); nitrogen (blue); oxygen (red); and sulfur (yellow). 602 
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 603 
Figure 2. Hollow fiber infection model of cryptococcal meningitis.  A, pharmacokinetics of 604 
flubendazole with the three arms with intended peak concentrations of 1.25, 2.5 and 10 mg/L; 605 
and B, pharmacodynamics in response to flubendazole administered at various dosages q24h.  606 
Therapy was initiated 24 hrs. post inoculation after which time Cryptococcus had grown from ~6 607 
log10CFU/mL to 8 log10CFU/mL. 608 
  609 
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 610 
 611 
Figure 3. Flubendazole pharmacokinetics in mice and rabbits. A, mouse plasma concentration-612 
time profiles following the administration of flubendazole 2, 4, 6, 8 and 12 mg/kg; B, mouse 613 
concentration-time profiles in the brain following the administration of flubendazole 2, 4, 6, 8 614 
and 12 mg/kg.  Data are mean ± standard deviation of n=3 mice.  C, plasma pharmacokinetics in 615 
the serum for individual rabbits receiving 6 mg/kg/day (broken lines, solid triangles) and 22.5 616 
mg/kg (solid lines, solid squares). 617 
  618 
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 619 
 620 
 621 
Figure 4. Pharmacodynamics of flubendazole in a murine model of cryptococcal meningitis.  622 
Flubendazole is administered orally once daily.  Data (open squares) are mean ± standard 623 
deviation from n=3 mice.  The solid line is the fit of the population predicted pharmacokinetic-624 
pharmacodynamic model.  The maximally administered dose in this study (12 mg/kg/day) 625 
slowed, but did not prevent fungal growth in the brain. 626 
   627 
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 628 
 629 
 630 
 631 
Figure 5. Pharmacodynamics of flubendazole in a rabbit model of cryptococcal meningitis.  A, 632 
time-course of fungal burden in the CSF of untreated controls; B, time-course of fungal burden in 633 
the CSF rabbits treated with flubendazole 6 mg/kg q24h orally; C, time-course of fungal burden 634 
in the CSF rabbits treated with flubendazole 22.5 mg/kg q24h orally; D, the fungal burden in the 635 
cerebrum of rabbits at the end of the experiment (time = 288 hrs. post inoculation and after 10 636 
days of treatment with flubendazole).  There are no differences in the three groups (p=0.464, 637 
ANOVA). 638 
 639 
 o
n
 January 15, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
